• Boston Biomedical Discontinues Napabucasin Study americanpharmaceuticalreview
    July 04, 2019
    Boston Biomedical has announced the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with ...
PharmaSources Customer Service